On Thursday, Shares of Nektar Therapeutics (NASDAQ:NKTR), gained 2.90% to $13.84.
Nektar Therapeutics, and The University of Texas MD Anderson Cancer Center declared a research partnership that comprises a Phase 1/2 clinical study to evaluate NKTR-214, a CD122-biased cytokine designed to preferentially stimulate production of CD8-positive T cells, which are tumor killing cells found naturally in the body. CD122, which is also known as the Interleukin-2 receptor beta sub-unit, is a key signaling receptor that is known to enhance proliferation of these effector T cells.
The agreement covers a Phase 1/2 study to evaluate NKTR-214 in a variety of tumor types as a monotherapy and in combination with other therapies, counting PD-1 pathway inhibitors. Nektar and MD Anderson expect to initiate the first dose-escalation clinical study later this year. The two organizations will also conduct translational research to identify predictive biomarkers that can be used in the future development of NKTR-214.
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.
Shares of ICICI Bank Ltd. (NYSE:IBN), inclined 0.48% to $10.52, during its last trading session, despite financial stocks ended moderately lower Thursday afternoon with the NYSE Financial Sector Index slipping 0.2% and the S&P Financial 100 Index declining 0.4%.
ICICI Bank Limited, together with its subsidiaries, provides banking and financial services in India and internationally. The company operates through Retail Banking, Wholesale Banking, Treasury, Other Banking, Life Insurance, General Insurance, and Others segments.
Finally, Bristol-Myers Squibb Company (NYSE:BMY), ended its last trade with 0.04% gain, and closed at $66.84.
Bristol-Myers Squibb Company, declared important next steps in the evolution of the company’s R&D organization, counting plans to expand its presence within hubs of scientific excellence and innovation with the opening of a new state-of-the-art research site in Cambridge, Mass. in addition to the ongoing expansion of the company’s R&D Discovery site in the San Francisco Bay Area. The new facility in Cambridge, which will be located at 100 Binney Street in Kendall Square, is predictable to open in 2018. The ongoing site expansion in the San Francisco Bay Area adds 61,000 square feet of laboratory and office space at the Woodside Technology Park life science campus and is predictable to be accomplished in 2016. Consistent with evolution of the R&D organization’s planned focus, which was formerly declared in 2013, the company also declared recently its plans to discontinue discovery research efforts in virology. This decision does not impact the company’s promising ongoing clinical development program in virology, nor does it impact the company’s marketed products in virology.
“In addition to investments in central New Jersey, our new location in Cambridge and our expanding presence in the San Francisco Bay area positions the company and our scientists in the heart of vibrant ecosystems of world class science, innovation and business opportunities, which offer ideal environments for fostering external collaboration,” said Francis Cuss, MB BChir, FRCP, executive vice president and chief scientific officer, Bristol-Myers Squibb. “Ultimately, our aim is to continue to accelerate the translation of scientific knowledge and insights into the next wave of potentially transformational medicines for patients with serious diseases.”
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
